Catalog No.

KDE84601

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Codrituzumab

Alternative Names

GC33, RG7686, RO5137382, CAS: 1365267-33-9

Background

Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer. The specific expression of GPC3 is high in hepatocellular carcinoma (HCC) tissues, which suggests that GPC3 has obvious sensitivity and specificity in the diagnosis of hepatocellular carcinoma, and can be used as a new target for the treatment of hepatocellular carcinoma. Codrituzumab did not show significant inhibition of GPC3 in the phase I trial in combined with sorafenib and the phase II trial placebo-controlled study in patients with advanced liver cancer. Codrituzumab did not show significant inhibition of GPC3 in phase I trials and phase II trials combined with sorafenib in patients with advanced liver cancer. However, the effect of codrituzumab in the treatment of liver cancer is still under study. In 2018, researchers conducted trials such as the distribution of codrituzumab and the impact of overall survival in patients with hepatocellular carcinoma. In the combined analysis of tumor cell surface antigen GPC3 and NK cell surface antigen CD16 in patients with liver cancer, it was found that codrituzumab only had a certain therapeutic effect on patients with high expression level of GPC3 and CD16. These results suggest that GPC3 and CD16 can be used as a composite biomarker to select hepatocellular carcinoma patients for codrituzuma.

Shipping

2-8 ℃

Note

For Research Use Only.

Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.

AntibodySystem由具有30多年蛋白抗體開(kāi)發(fā)經(jīng)驗的 創(chuàng )立于法國,專(zhuān)注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開(kāi)發(fā)了高效、高產(chǎn)的真核重組表達系統,利用該系統生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區授權 ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準